EditorialKommentar
RIPK2 inhibition gets the NOD for asthma
European Respiratory Journal · 2024
DOI: 10.1183/13993003.01372-2024 ↗Kurz gefasst
Editorial in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Henry J McSorley. Beteiligte Einrichtung: School of Life Sciences, University of Dundee, Dundee, UK hmcsorley001@dundee.ac.uk. Hauptthemen laut MEDLINE: Asthma, Receptor-Interacting Protein Serine-Threonine Kinase 2. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AsthmaReceptor-Interacting Protein Serine-Threonine Kinase 2HumansAnimalsMiceNod2 Signaling Adaptor Protein
Substanzen
Receptor-Interacting Protein Serine-Threonine Kinase 2Nod2 Signaling Adaptor Protein
Autor:innen und Institutionen
- School of Life Sciences, University of Dundee, Dundee, UK hmcsorley001@dundee.ac.uk.
Zitieren
APA
McSorley, H. J. (2024). RIPK2 inhibition gets the NOD for asthma. European Respiratory Journal. https://doi.org/10.1183/13993003.01372-2024
Vancouver
McSorley HJ. RIPK2 inhibition gets the NOD for asthma. European Respiratory Journal. 2024. doi:10.1183/13993003.01372-2024
BibTeX
@article{McSorley2024,
author = {McSorley, Henry J},
title = {RIPK2 inhibition gets the NOD for asthma},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.01372-2024}
}
EUVIMED